PHARM Chapter 26 - Hypothalamus and Pituitary Gland Flashcards
3 Drugs for Growth hormone and insulin like growth factor replacement
Somatorpin (GH)/Somatrem
Semorelin (GRRH)/Tesamorelin
Mecasermine
ME of Growth Hormone and Insulin LIke Growth Factor Replacement
stimulate release of or replace growth hormone or insulin like growth hormone
Use of Somatorpin (GH) and Somatrem
Growth failure in children w/ GH deficiency
Turners syndrom
Prader Willi syndrome
Chronic kidney disease
Idiopathic short stature
Replacement of endogenous GH in adults w/ GH deficiency
Use of Sermorelin (GHRH) and Tesamorelin
Diagnostic evaluation of decreased plasma growth hormone (sermorelin) HIV lipodystrophy (tesamorelin)
Use of Mecasermin
Laron dwarfism, DH deficiency w/ neutralizing antibodies
Contraindication for Growth Hormone and Insulin-like growth replacement
active malignancy
Recombinant IGF-1
mecasermin
Why does IGF-1 serve as better measurement
bound and stable in the circulation for longer peroids of time at steady concentrations
Endogenous biological inputs that promote GH release include
GHRH, sex steroids, dopamine, ghrelin
Ghrelin acts w/ ___ to prommote GH release
GHRH
What is the most common cause of GH deficiency
defective hypothalamic release of GHRH, pituitary insufficiency, failure of IGF-1 secretion in response to GH
Alternative exogenous agents used to stimulate GH release
glucagon, arginine, clonide, and insulin
What is the main treatment for growth hormone excess
somatostatin receptor ligands
2 agnts that decrease growth horone secretion or action
Octreotide and pegvisomant
ME of octreotide and pegvisomant
inhibit GH release (octreotide)
antagonize GH receptor (pegvisomant)
Uses of Octreotide
acromegaly
able to control GI bleeding and reduce secretory diarrhea
flushing and diarrhea from carcinoid tumors
carcinoid crisis
diarrhea from vasoactive intestinal peptide-secreting tumors
TSH producing adenomas
Uses of pegvisomant
acromegaly
Contraindication for pegvisomant
known malignancy, pt. should have yearly MRI
Works on lactotrophs to physiologically inhibit prolactin release
dopamine
2 dopamine analogues
bromocriptine
cabergoline
GH analogue modified at one site to bind to GH w/ higher affinity than native model, preventing receptor dimerization required for subsequent receptor activation
Pegvisomant
How are lactotrophs unlike other cells of anterior pituitary
under tonic inhibition by the hypothalamus, mediated by dopamine - therefore in disease states, while other hormones will be decreased, prolactin will increase
What stimulates lactotrophs to secrete increasing quantities of prolactin
estrogen - although prolactin negatively feedbacks to suppress estrogen
How does prolactin negatively feedback to suppress estrogen
antagonizes hypothalamic release of GnRH and by decreasing gonadotroph sensitivity to GNRH
Agents that decrease prolactin levels
bromocriptine
cabergoline
Uses of bromocriptine
amenorrhea and galactorrhea from hyperprolactinemia
acromegaly
Parkinson’s
Premenstrual syndrome